Human Papillomavirus and Genital Warts: A Review of the Evidence for the 2015 Centers for Disease Control and Prevention Sexually Transmitted Diseases Treatment Guidelines

Clinical Infectious Diseases

Volumn 61, Issue , 2015, Pages S849-S855

  Park, Ina U ^a,b   Introcaso, Camille ^c   Dunne, Eileen F ^c  

^a Division of Communicable Disease Control   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

genital warts; HPV; HPV vaccine; treatment

Indexed keywords

DICHLOROACETIC ACID; GREEN TEA EXTRACT; IMIQUIMOD; PODOPHYLLOTOXIN; TRICHLOROACETIC ACID; WART VIRUS VACCINE; AMINOQUINOLINE DERIVATIVE; ANTIVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANUS CANCER; ANUS CARCINOMA; ARTICLE; BEDTIME DOSAGE; CANCER SCREENING; CAUTERIZATION; CONDYLOMA ACUMINATUM; CRYOTHERAPY; FEMALE; HEALTH CARE COST; HEALTH CARE PERSONNEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MEN WHO HAVE SEX WITH MEN; OCCUPATIONAL EXPOSURE; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; WART VIRUS; ADOLESCENT; ANUS NEOPLASMS; COMPLICATION; CONDYLOMATA ACUMINATA; PAPILLOMAVIRUS INFECTIONS; PREVALENCE; PUBLIC HEALTH SERVICE; TRANSMISSION; UNITED STATES; VIROLOGY; YOUNG ADULT;

ADOLESCENT; AMINOQUINOLINES; ANTIVIRAL AGENTS; ANUS NEOPLASMS; CENTERS FOR DISEASE CONTROL AND PREVENTION (U.S.); CONDYLOMATA ACUMINATA; FEMALE; HIV INFECTIONS; HUMANS; MALE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PRACTICE GUIDELINES AS TOPIC; PREVALENCE; UNITED STATES; YOUNG ADULT;

EID: 84950277162     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ813     Document Type: Article

References (68)

1. Chesson HW, Dunne EF, Hariri S, Markowitz LE. The estimated lifetime probability of acquiring human papillomavirus in the United States. Sex Transm Dis 2014; 41:660-4.
2. Satterwhite CL, Torrone E, Meites E, et al. Sexually transmitted infections among US women and men: prevalence and incidence estimates, 2008. Sex Transm Dis 2013; 40:187-93.
3. Jemal A, Simard EP, Dorell C, et al. Annual report to the nation on the status of cancer, 1975-2009, featuring the burden and trends in human papillomavirus (HPV)-associated cancers and HPV vaccination coverage levels. J Natl Cancer Inst 2013; 105:175-201.
4. Chesson HW, Ekwueme DU, Saraiya M, Dunne EF, Markowitz LE. The cost-effectiveness of male HPV vaccination in the United States. Vaccine 2011; 29:8443-50.
5. Patel H, Wagner M, Singhal P, Kothari S. Systematic review of the incidence and prevalence of genital warts. BMC Infect Dis 2013; 13:39.
6. Hoy T, Singhal PK, Willey VJ, Insinga RP. Assessing incidence and economic burden of genital warts with data from a US commercially insured population. Curr Med Res Opin 2009; 25:2343-51.
7. Winer RL, Hughes JP, Feng Q, et al. Early natural history of incident, type-specific human papillomavirus infections in newly sexually active young women. Cancer Epidemiol Biomarkers Prev 2011; 20:699-707.
8. Giuliano AR, Lee J-H, Fulp W, et al. Incidence and clearance of genital human papillomavirus infection in men (HIM): a cohort study. Lancet 2011; 377:932-40.
9. Widdice L, Ma Y, Jonte J, et al. Concordance and transmission of human papillomavirus within heterosexual couples observed over short intervals. J Infect Dis 2013; 207:1286-94.
10. Mbulawa ZZ, Johnson LF, Marais DJ, Coetzee D, Williamson AL. The impact of human immunodeficiency virus on human papillomavirus transmission in heterosexually active couples. J Infect 2013; 67:51-8.
11. Hernandez BY, Wilkens LR, Zhu X, et al. Transmission of human papillomavirus in heterosexual couples. Emerg Infect Dis 2008; 14:888-94.
12. Burchell AN, Coutlee F, Tellier PP, Hanley J, Franco EL. Genital transmission of human papillomavirus in recently formed heterosexual couples. J Infect Dis 2011; 204:1723-9.
13. Anic GM, Lee JH, Stockwell H, et al. Incidence and human papillomavirus (HPV) type distribution of genital warts in a multinational cohort of men: the HPV in men study. J Infect Dis 2011; 204:1886-92.
14. Arima Y, Winer RL, Feng Q, et al. Development of genital warts after incident detection of human papillomavirus infection in young men. J Infect Dis 2010; 202:1181-4.
15. Garland SM, Steben M, Sings HL, et al. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J Infect Dis 2009; 199:805-14.
16. Winer RL, Kiviat NB, Hughes JP, et al. Development and duration of human papillomavirus lesions, after initial infection. J Infect Dis 2005; 191:731-8.
17. Massad LS, Xie X, Darragh T, et al. Genital warts and vulvar intraepithelial neoplasia: natural history and effects of treatment and human immunodeficiency virus infection. Obstet Gynecol 2011; 118:831-9.
18. Blomberg M, Friis S, Munk C, Bautz A, Kjaer SK. Genital warts and risk of cancer: a Danish study of nearly 50 000 patients with genital warts. J Infect Dis 2012; 205:1544-53.
19. Schlecht HP, Fugelso DK, Murphy RK, et al. Frequency of occult highgrade squamous intraepithelial neoplasia and invasive cancer within anal condylomata in men who have sex with men. Clin Infect Dis 2010; 51:107-10.
20. Maniar KP, Ronnett BM, Vang R, Yemelyanova A. Coexisting highgrade vulvar intraepithelial neoplasia (VIN) and condyloma acuminatum: independent lesions due to different HPV types occurring in immunocompromised patients. Am J Surg Pathol 2013; 37:53-60.
21. Zyclara [package insert]. Scottsdale AZ: Medicis, The Dermatology Company, 2012.
22. Baker DA, Ferris DG, Martens MG, et al. Imiquimod 3.75% cream applied daily to treat anogenital warts: combined results from women in two randomized, placebo-controlled studies. Infect Dis Obstet Gynecol 2011; 2011:806105.
23. Schirren CG Sr. Severe generalized poisoning following local application of podophyllin alcohol in pointed condyloma [in German]. Hautarzt 1966; 17:321-2.
24. Montaldi DH, Giambrone JP, Courey NG, Taefi P. Podophyllin poisoning associated with the treatment of condyloma acuminatum: a case report. Am J Obstet Gynecol 1974; 119:1130-1.
25. Slater GE, Rumack BH, Peterson RG. Podophyllin poisoning. Systemic toxicity following cutaneous application. Obstet Gynecol 1978; 52:94-6.
26. Stoehr GP, Peterson AL, Taylor WJ. Systemic complications of local podophyllin therapy. Ann Intern Med 1978; 89:362-3.
27. Filley CM, Graff-Richard NR, Lacy JR, Heitner MA, Earnest MP. Neurologic manifestations of podophyllin toxicity. Neurology 1982; 32:308-11.
28. Ward JW, Clifford WS, Monaco AR, Bickerstaff HJ. Fatal systemic poisoning following podophyllin treatment of condyloma acuminatum. South Med J 1954; 47:1204-6.
29. Conard PF, Hanna N, Rosenblum M, Gross JB. Delayed recognition of podophyllum toxicity in a patient receiving epidural morphine. Anesth Analg 1990; 71:191-3.
30. Chamberlain MJ, Reynolds AL, Yeoman WB. Medical memoranda. toxic effect of podophyllum application in pregnancy. Br Med J 1972; 3:391-2.
31. Andre P, Orth G, Evenou P, Guillaume JC, Avril MF. Risk of papillomavirus infection in carbon dioxide laser treatment of genital lesions. J Am Acad Dermatol 1990; 22:131-2.
32. Garden JM, O'Banion MK, Bakus AD, Olson C. Viral disease transmitted by laser-generated plume (aerosol). Arch Dermatol 2002; 138:1303-7.
33. Ferenczy A, Bergeron C, Richart RM. Human papillomavirus DNA in CO2 laser-generated plume of smoke and its consequences to the surgeon. Obstet Gynecol 1990; 75:114-8.
34. Sood AK, Bahrani-Mostafavi Z, Stoerker J, Stone IK. Human papillomavirus DNA in LEEP plume. Infect Dis Obstet Gynecol 1994; 2:167-70.
35. Ilmarinen T, Auvinen E, Hiltunen-Back E, Ranki A, Aaltonen LM, Pitkaranta A. Transmission of human papillomavirus DNA from patient to surgical masks, gloves and oral mucosa of medical personnel during treatment of laryngeal papillomas and genital warts. Eur Arch Otorhinolaryngol 2012; 269:2367-71.
36. Kashima HK, Kessis T, Mounts P, Shah K. Polymerase chain reaction identification of human papillomavirus DNA in CO2 laser plume from recurrent respiratory papillomatosis. Otolaryngol Head Neck Surg 1991; 104:191-5.
37. Bergbrant IM, Samuelsson L, Olofsson S, Jonassen F, Ricksten A. Polymerase chain reaction for monitoring human papillomavirus contamination of medical personnel during treatment of genital warts with CO2 laser and electrocoagulation. Acta Derm Venereol 1994; 74:393-5.
38. Hallmo P, Naess O. Laryngeal papillomatosis with human papillomavirus DNA contracted by a laser surgeon. Eur Arch Otorhinolaryngol 1991; 248:425-7.
39. Calero L, Brusis T. Laryngeal papillomatosis-first recognition in Germany as an occupational disease in an operating room nurse [in German]. Laryngorhinootologie 2003; 82:790-3.
40. Machalek DA, Poynten M, Jin F, et al. Anal human papillomavirus infection and associated neoplastic lesions in men who have sex with men: a systematic review and meta-analysis. Lancet Oncol 2012; 13:487-500.
41. de Pokomandy A, Rouleau D, Ghattas G, et al. HAART and progression to high-grade anal intraepithelial neoplasia in men who have sex with men and are infected with HIV. Clin Infect Dis 2011; 52:1174-81.
42. Palefsky JM, Holly EA, Ralston ML, Jay N, Berry JM, Darragh TM. High incidence of anal high-grade squamous intra-epithelial lesions among HIV-positive and HIV-negative homosexual and bisexual men. AIDS 1998; 12:495-503.
43. Berry JM, Palefsky JM, Jay N, Cheng SC, Darragh TM, Chin-Hong PV. Performance characteristics of anal cytology and human papillomavirus testing in patients with high-resolution anoscopy-guided biopsy of high-grade anal intraepithelial neoplasia. Dis Colon Rectum 2009; 52:239-47.
44. Salit IE, Lytwyn A, Raboud J, et al. The role of cytology (Pap tests) and human papillomavirus testing in anal cancer screening. AIDS 2010; 24:1307-13.
45. Mathews WC, Agmas W, Cachay E. Comparative accuracy of anal and cervical cytology in screening for moderate to severe dysplasia by magnification guided punch biopsy: a meta-analysis. PLoS One 2011; 6:e24946.
46. Nathan M, Singh N, Garrett N, Hickey N, Prevost T, Sheaff M. Performance of anal cytology in a clinical setting when measured against histology and high-resolution anoscopy findings. AIDS 2010; 24:373-9.
47. Salit IE, Tinmouth J, Chong S, et al. Screening for HIV-associated anal cancer: correlation of HPV genotypes, p16, and E6 transcripts with anal pathology. Cancer Epidemiol Biomarkers Prev 2009; 18:1986-92.
48. Czoski-Murray C, Karnon J, Jones R, Smith K, Kinghorn G. Cost-effectiveness of screening high-risk HIV-positive men who have sex with men (MSM) and HIV-positive women for anal cancer. Health Technol Assess 2010; 14:iii-iv, ix-x, 1-101.
49. Karnon J, Jones R, Czoski-Murray C, Smith KJ. Cost-utility analysis of screening high-risk groups for anal cancer. J Public Health (Oxf) 2008; 30:293-304.
50. Lam JM, Hoch JS, Tinmouth J, Sano M, Raboud J, Salit IE. Costeffectiveness of screening for anal precancers in HIV-positive men. AIDS 2011; 25:635-42.
51. Tinmouth J, Raboud J, Ali M, et al. The psychological impact of being screened for anal cancer in HIV-infected men who have sex with men. Dis Colon Rectum 2011; 54:352-9.
52. Landstra JM, Ciarrochi J, Deane FP, Botes LP, Hillman RJ. The psychological impact of anal cancer screening on HIV-infected men. Psychooncology 2013; 22:614-20.
53. Siekas LL, Aboulafia DM. Establishing an anal dysplasia clinic for HIVinfected men: initial experience. AIDS Read 2009; 19:178-86.
54. Palefsky JM, Giuliano AR, Goldstone S, et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med 2011; 365:1576-85.
55. Macaya A, Munoz-Santos C, Balaguer A, Barbera MJ. Interventions for anal canal intraepithelial neoplasia. Cochrane Database Syst Rev 2012; 12:CD009244.
56. Fox PA, Nathan M, Francis N, et al. A double-blind, randomized controlled trial of the use of imiquimod cream for the treatment of anal canal high-grade anal intraepithelial neoplasia in HIV-positive MSM on HAART, with long-term follow-up data including the use of open-label imiquimod. AIDS 2010; 24:2331-5.
57. Richel O, Wieland U, de Vries HJ, et al. Topical 5-fluorouracil treatment of anal intraepithelial neoplasia in human immunodeficiency viruspositive men. Br J Dermatol 2010; 163:1301-7.
58. Stier EA, Goldstone SE, Berry JM, et al. Infrared coagulator treatment of high-grade anal dysplasia in HIV-infected individuals: an AIDS malignancy consortium pilot study. J Acquir Immune Defic Syndr 2008; 47:56-61.
59. Goldstone RN, Goldstone AB, Russ J, Goldstone SE. Long-term followup of infrared coagulator ablation of anal high-grade dysplasia in men who have sex with men. Dis Colon Rectum 2011; 54:1284-92.
60. Marks DK, Goldstone SE. Electrocautery ablation of high-grade anal squamous intraepithelial lesions in HIV-negative and HIV-positive men who have sex with men. J Acquir Immune Defic Syndr 2012; 59:259-65.
61. Cranston RD, Hirschowitz SL, Cortina G, Moe AA. A retrospective clinical study of the treatment of high-grade anal dysplasia by infrared coagulation in a population of HIV-positive men who have sex with men. Int J STD AIDS 2008; 19:118-20.
62. Singh JC, Kuohung V, Palefsky JM. Efficacy of trichloroacetic acid in the treatment of anal intraepithelial neoplasia in HIV-positive and HIVnegative men who have sex with men. J Acquir Immune Defic Syndr 2009; 2:474-9.
63. Pineda CE, Berry JM, Jay N, Palefsky JM, Welton ML. High-resolution anoscopy targeted surgical destruction of anal high-grade squamous intraepithelial lesions: a ten-year experience. Dis Colon Rectum 2008; 51:829-35, discussion 835-7.
64. Sirera G, Videla S, Pinol M, et al. Long-term effectiveness of infrared coagulation for the treatment of anal intraepithelial neoplasia grades 2 and 3 in HIV-infected men and women. AIDS 2013; 27:951-9.
65. Nathan M, Hickey N, Mayuranathan L, Vowler SL, Singh N. Treatment of anal human papillomavirus-associated disease: a long term outcome study. Int J STD AIDS 2008; 19:445-9.
66. Weis SE, Vecino I, Pogoda JM, Susa JS. Treatment of high-grade anal intraepithelial neoplasia with infrared coagulation in a primary care population of HIV-infected men and women. Dis Colon Rectum 2012; 55:1236-43.
67. Markowitz LE, Dunne EF, Saraiy M, et al. Human papillomavirus vaccination: recommendation of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep 2014; 63(RR-05):1-30.
68. Petrosky E, Bocchini JA Jr, Hariri S, et al. Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep 2015; 64:300-4